New Funding for Clinical Endocrinology Quality Improvement Projects available from the Clinical Endocrinology Trust
The Clinical Endocrinology Trust has long supported Endocrine Audit projects within the UK. Recent examples include the UK Acromegaly Database, the CaHASE audit of adults with CAH, and a BTA study of teenage iodine status across the UK. The Trustees now invite further applications from Societies or Endocrine Centres within the UK. Preference will be given to projects involving multicentre collaborations. We are particularly interested in receiving applications related to areas of endocrinology the Trust has not supported previously. A total sum of £50,000 is available during 2014-2015 for a number of projects judged by the Trustees to be worthy of support. Their decision will be final. The trustees require that projects are commenced within six months of an award being made. Application forms are available from Judith.email@example.com The deadline for applications is 30 June 2014. Applications should be sent to Professor Julian Davis (CET Secretary) at firstname.lastname@example.org.
Condition: Acromegaly Due to Pituitary Adenoma Interventions: Other: GIP-A; Other: Placebo Sponsors: University of Copenhagen; Rigshospitalet, Denmark; Aarhus University Hospital; Aalborg Universitetshospital; Odense University Hospital; Herlev and Gentofte Hospital Not yet recruiting
Authors: Goltzman D Abstract Primary hyperparathyroidism is among the most common causes of hypercalcemia. However, ingestion of medication, including hydrochlorathiazide, lithium, and foscarnet, excessive vitamin A ingestion, endocrinopathies such as hyperthyroidism, adrenal insufficiency, and acromegaly, abnormal nutrient intake such as parenteral nutrition in preterm infants and milk-alkali syndrome, and prolonged immobilization have all been associated with hypercalcemia. The most common cause of nonparathyroid hypercalcemia is neoplasia. Hypercalcemia is generally due to the secretion of parathyroid hormone (P...
Conclusions:MEN1 alterations can be of significance in FIPA patients and screening could be offered toAIP mutation-negative patients without MEN1 features. Further studies are needed to clarify the role ofMEN1 in FIPA patients.Pathobiology
Publication date: 2019Source: Advances in Virus Research, Volume 103Author(s): Eugene V. Koonin, Natalya YutinAbstractThe Nucleocytoplasmic Large DNA Viruses (NCLDV) of eukaryotes (proposed order “Megavirales”) comprise an expansive group of eukaryotic viruses that consists of the families Poxviridae, Asfarviridae, Iridoviridae, Ascoviridae, Phycodnaviridae, Marseilleviridae, Pithoviridae, and Mimiviridae, as well as Pandoraviruses, Molliviruses, and Faustoviruses that so far remain unaccounted by the official virus taxonomy. All these viruses have double-stranded DNA genomes that range in size from about 100 k...
ConclusionAll five ACRODAT ® parameters had some influence on disease activity from the patients’ perspective. To account for patients’ preferences and optimize treatment and outcomes, a holistic disease management approach should be employed.
ConclusionThis study described the profiles of acromegaly in Taiwan. It is important to enhance early diagnosis and timely commencement of treatment to prevent serious complications of acromegaly.
We report an unusual plurihormonal tumor co-expressing Pit-1 and SF-1 along with hormones made by cells of both lineages. Its simultaneous occurrence adjacent to a corticotroph tumor raises questions regarding the pathogenesis of these tumors. We pr opose the possibility of a stem cell tumor with multiple lineage differentiation. We hypothesize that pregnancy might have played a permissive role in tumorigenesis.
Publication date: March–April 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 13, Issue 2Author(s): Leila Moradi, Fatemeh Amiri, Hajieh ShahbazianAbstractPatients with acromegaly have soft tissue overgrowth that induced characteristic clinical presentation. A growth hormone-secreting adenoma of the anterior pituitary gland is the most common cause of acromegaly. Metabolic and somatic features of acromegaly caused by high serum concentrations of insulin-like growth factor-I (IGF-I) and excess growth hormone (GH) production. we present a case of ‘pseudoacromegaly’ with a...
Condition: Acromegaly Interventions: Drug: CRN00808; Drug: Placebo Sponsor: Crinetics Pharmaceuticals Inc. Recruiting